CABA

Cabaletta Bio, Inc. CABA

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-51.02M

Quarter to Jun 30

Free cash flow

$-41.51M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$490.44M total
JENNISON ASSOCIATES LLC
$62.30M+123.3%
T. Rowe Price Investment Management, Inc.
$58.69M+70.3%
Bain Capital Life Sciences Investors, LLC
$53.62M+78.2%
BlackRock, Inc.
$33.45M+353.2%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$28.53M+3.9%
STATE STREET CORP
$24.38M+1568.0%
VANGUARD CAPITAL MANAGEMENT LLC
$22.48M+79.4%
Cormorant Asset Management, LP
$15.55M-9.1%
PRICE T ROWE ASSOCIATES INC /MD/
$13.74M+899.1%
Woodline Partners LP
$13.06M+235.9%
NORGES BANK
$12.79M--
Opaleye Management Inc.
$12.02M+180.0%
CITADEL ADVISORS LLC
$10.95MNew
GEODE CAPITAL MANAGEMENT, LLC
$10.76M+205.3%
FRANKLIN RESOURCES INC
$7.51MNew
GOLDMAN SACHS GROUP INC
$6.88M+182.4%
MILLENNIUM MANAGEMENT LLC
$6.43M-65.0%
MARSHALL WACE, LLP
$4.87M-28.2%
RENAISSANCE TECHNOLOGIES LLC
$4.77M-24.6%
UBS Group AG
$4.58M+142.6%
Qube Research & Technologies Ltd
$4.44M-26.3%
VANGUARD PORTFOLIO MANAGEMENT LLC
$4.41MNew
TWO SIGMA INVESTMENTS, LP
$4.39M-43.5%
MORGAN STANLEY
$4.18M-4.4%
SPHERA FUNDS MANAGEMENT LTD.
$4.13MNew
See all 141 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/CABA

Earnings Per Share

13fpro.ai/company/CABA

Loading ratio trend…

CABA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Cabaletta Bio, Inc. (CABA): stock profile, AI score and financials

Cabaletta Bio, Inc. (CABA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. CABA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Cabaletta Bio, Inc. reports net income of $-51.0M, free cash flow of $-41.5M. Top institutional holders of CABA by reported 13-F value include JENNISON ASSOCIATES, T. Rowe Price Investment Management, Bain Capital Life Sciences Investors, based on the most recent SEC filings. CABA trades on the Nasdaq exchange and files with the SEC under CIK 1759138. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CABA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cabaletta Bio, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1759138 →